Kailera Therapeutics reported cash from operations of -$133.67M and free cash flow of -$133.67M for the quarter ended Sep 2026, down 350.1% year over year. This cash flow statement covers 8 quarters of results from Dec 2024 through Sep 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow StatementCash Flow | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 | Sep2026 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | -17.98M | -28.95M | -39.62M | -62.40M | -78.87M | -111.31M | -95.67M | |
| Depreciation, Depletion & Amortization | ||||||||
| Depreciation & Amortization (CF)Dep. & Amort. | 0.06M | 0.06M | 0.06M | 0.12M | 0.10M | 0.10M | 0.10M | |
| Share-based CompensationStock Comp. | 1.52M | 1.63M | 4.27M | 3.52M | 3.94M | 8.34M | 9.92M | |
| Other non-cash itemsOther Non-Cash | 0.81M | -0.67M | -1.88M | 0.34M | -0.31M | -0.26M | -0.27M | |
| Change in Working Capital | ||||||||
| Change in Account PayablesChange Payables | 0.65M | -0.84M | 0.15M | 4.73M | -0.50M | 12.34M | -9.77M | |
| Change in Accrued ExpensesChange Accrued Exp. | 1.06M | 6.14M | 5.12M | 20.98M | 9.38M | 15.05M | -30.55M | |
| Change in Other Operating AssetsOther Assets Change | 2.68M | 3.66M | 1.30M | -16.40M | -0.07M | -1.00M | 5.85M | |
| Change in Other Operating LiabilitiesOther Liabilities Change | -0.30M | -0.12M | 0.02M | -0.35M | -0.32M | -0.31M | ||
| Other Working Capital ChangesOther WC Changes | -2.68M | -3.96M | -1.42M | 16.42M | -0.28M | 0.68M | -6.16M | |
| Cash from OperationsCash from Ops. | -18.20M | -26.23M | -29.70M | -46.08M | -68.31M | -77.53M | -133.67M | |
| Investing Activities | ||||||||
| Capital ExpendituresCapex | -2.53M | |||||||
| Change in Property, Plant and EquipmentChange in PP&E | 2.53M | |||||||
| Purchase of InvestmentsInvestments Purchased | 54.44M | 82.17M | 42.28M | -811.05M | 48.45M | 689.81M | 37.06M | |
| Sale and Maturity of InvestmentsInvestments Sold | 8.00M | 69.21M | 64.44M | 71.30M | 118.79M | 147.89M | ||
| Other Investing Activities (as filed)Other investing (as filed) | 0.76M | 0.76M | ||||||
| Cash from Investing ActivitiesCash from Investing | -54.44M | -74.17M | 26.48M | -390.47M | 22.85M | -571.02M | 110.83M | |
| Financing Activities | ||||||||
| Change in Capital Stock | ||||||||
| Common Stock IssuedStock Issued | 0.10M | 0.06M | 668.87M | 0.34M | ||||
| Shares Repurchased | 3.04M | -7.92M | ||||||
| Net Shares Issued and RepurchasedNet Shares Issued | 0.10M | -2.98M | 676.78M | 0.34M | ||||
| Net Equity Issued and RepurchasedNet Equity Issued | 0.10M | -2.98M | 676.78M | 0.34M | ||||
| Cash from Financing ActivitiesCash from Financing | 100.00M | -0.24M | 498.90M | -2.98M | 667.03M | -0.92M | ||
| Additional items | ||||||||
| Change in Cash | -72.64M | -0.40M | -3.46M | 62.35M | -48.44M | 18.48M | -23.76M | |
| Beginning Cash Balance | -237.70M | -266.64M | -306.27M | -447.53M | 1,679.10M | 1,689.36M | ||
| Ending Cash Balance | 175.18M | 102.54M | 102.13M | 98.68M | 161.03M | 112.59M | 131.06M | 107.30M |
| Free Cash FlowFCF | -18.20M | -26.23M | -29.70M | -43.55M | -68.31M | -77.53M | -133.67M | |
| Net Cash FlowNCF | -72.64M | -0.40M | -3.46M | 62.35M | -48.44M | 18.48M | -23.76M |
Pull Kailera Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=KLRA&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "KLRA", "statement": "CF", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=KLRA&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();